Users Discontinuing Slimming Injections Regain Pounds Four Times Faster Than Those on Conventional Diets

A recent study suggests that people who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who end conventional diet and exercise regimens.

Findings released in a major medical journal demonstrates that while obese people often shed about a fifth of their body weight while on the medication, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.

"People buying these drugs need to be informed of the potential of fast weight regain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.

Such speed of recovery means a return to original weight within about one and a half years.

Analyzing Therapies

The analysis, which examined 37 of trials involving over 9,000 of patients, compared the results of the injectable medications with other pills.

Scientists point out that individuals who lose weight through dieting usually see a slower weight regain—perhaps 100 grams monthly—after stopping.

Understanding the Quick Rebound

Nutrition scientists believe the way of the drugs explains the accelerated weight return.

The injections mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite.

"Long-term administration of the hormone concentrations several times higher than the body's typical production may cause the body to generate a reduced amount of its endogenous GLP-1, and could diminish responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.

"Stopping of this hormone supplement results in appetite is no longer kept in check, making excessive eating far more likely."

A Chronic Condition?

Health authorities suggest the jabs for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.

Professionals argue that, given the high risk of relapse, the treatment might need to be long-term.

This view is reinforced by drug manufacturers, who say that the findings "emphasize the long-term nature of excess weight," comparing it to managing diseases like diabetes.

Patient Accounts

People who have come off the jabs explain a intense return of cravings.

"It was like a switch flipping and I was suddenly ravenous," said a patient.

The struggle is compounded if individuals have not developed permanent lifestyle or habit changes during treatment.

Widespread Use

Survey data suggest that millions of people in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.

• Adoption is more common among women than males.
• The 40s and 50s demographic shows the highest level of interest.
• A large proportion access the medications through private healthcare rather than public health services.

Finally, clinicians emphasize that while the jabs are potent tools for shedding pounds, they are not a standalone fix and long-term success relies on ongoing behavioural management.